SS-31 vs Humanin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Elamipretide, Bendavia
A mitochondria-targeted peptide that improves cellular energy production. FDA approved for Barth syndrome (September 2025) as FORZINITY, the first approved mitochondria-targeted therapeutic.
Also: HN, HNG (S14G-humanin)
A mitochondria-derived peptide discovered for its neuroprotective effects against Alzheimer's-related toxicity. Being studied for aging and metabolic benefits.
Key Comparison Insights
- SS-31 is FDA approved, while Humanin remains in research stages.
- Both peptides belong to the Anti-Aging category, suggesting similar primary applications.
- SS-31 has stronger research evidence (FDA Approved) compared to Humanin (Animal Studies).
Detailed Comparison
| Attribute | SS-31 | Humanin |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | SS-31 concentrates 1000-fold in mitochondria, binding to cardiolipin on the inner membrane. It optimizes electron transport chain function, reduces reactive oxygen species, and prevents cardiolipin peroxidation during cellular stress. | Humanin acts through multiple pathways including STAT3 signaling, binding to IGFBP-3, and activating the FPRL1 receptor. It protects neurons from apoptosis, improves insulin sensitivity, and has anti-inflammatory effects. |
| Common Dosing | 40 mg subcutaneous daily Once daily | 5-10 mg weekly divided into 2-3 injections 2-3x weekly (e.g., Monday, Wednesday, Friday) |
| Administration | Subcutaneous injection or IV infusion | Injection (route varies) |
| Typical Duration | Variable by condition | Variable |
| Best Time to Take | Morning | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | FDA approved for Barth syndrome in September 2025 under accelerated approval. Ongoing trials for dry age-related macular degeneration and primary mitochondrial myopathy. Studies show improved cardiac function, exercise capacity, and mitochondrial efficiency. | Research shows protection against amyloid-beta toxicity in Alzheimer's models. Studies demonstrate improved insulin sensitivity, reduced atherosclerosis in animal models, and potential anti-aging effects. Human studies are limited. |
Frequently Asked Questions: SS-31 vs Humanin
What is the difference between SS-31 and Humanin?
SS-31 is a anti-aging peptide that a mitochondria-targeted peptide that improves cellular energy production. fda approved for barth syndrome (september 2025) as forzinity, the first approved mitochondria-targeted therapeutic. Humanin is a anti-aging peptide that a mitochondria-derived peptide discovered for its neuroprotective effects against alzheimer's-related toxicity. being studied for aging and metabolic benefits. The main differences lie in their mechanisms of action and clinical applications.
Which is better, SS-31 or Humanin?
Neither is universally "better" - the choice depends on your specific goals. SS-31 is typically used for anti-aging purposes, while Humanin is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can SS-31 and Humanin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using SS-31 and Humanin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.